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Abstract
Although the encapsulation of paclitaxel into liposomes has been extensively studied, its significant hydrophobic and
uncharged character has generated substantial difficulties concerning its efficient encapsulation into the inner water core of
liposomes. We found that a more hydrophilic paclitaxel molecule, 7-glucosyloxyacetylpaclitaxel, retained tubulin
polymerization stabilization activity. The hydrophilic nature of 7-glucosyloxyacetylpaclitaxel allowed its efficient
encapsulation into the inner water core of liposomes, which was successfully accomplished using a remote loading
method with a solubility gradient between 40% ethylene glycol and Cremophor EL/ethanol in PBS. Trastuzumab was then
conjugated onto the surface of liposomes as immunoliposomes to selectively target human epidermal growth factor
receptor-2 (HER2)-overexpressing cancer cells. In vitro cytotoxicity assays revealed that the immunoliposomes enhanced the
toxicity of 7-glucosyloxyacetylpaclitaxel in HER2-overexpressing cancer cells and showed more rapid suppression of cell
growth. The immunoliposomes strongly inhibited the tumor growth of HT-29 cells xenografted in nude mice. Notably, mice
survived when treated with the immunoliposomes formulation, even when administered at a lethal dose of 7-
glucosyloxyacetylpaclitaxel in vivo. This data successfully demonstrates immunoliposomes as a promising candidate for the
efficient delivery of paclitaxel glycoside.
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Introduction
Taxanes, such as paclitaxel (PTX) and docetaxel, comprise one
of the most effective classes of anticancer drugs that function by
stabilizing microtubules and inhibiting the cell cycle [1,2]. PTX
has been used for the treatment of breast, ovarian, colon, brain,
and non-small cell lung cancers. Because of the significant
hydrophobicity of PTX, the commercial formulation, Taxol,
contains the surfactant Cremophor EL and ethanol [1]. Since the
solvent is considered as the cause of the reported side effects of
Taxol [3], an alternative PTX formulation without the solvent has
been sought. Nanoparticles such as liposomes and micelles are
thought useful for producing PTX formulations that do not cause
the side effects associated with Cremophor EL and ethanol [1,4].
Liposomal drug delivery has been used to improve the
therapeutic effect of drugs in tumor cells by preventing significant
side effects in normal cells. Liposomes of particle size ranging from
100 to 200 nm can accumulate in solid tumors by enhanced
permeability and retention (EPR) effects because of the presence of
abnormal and leaky blood vessels and impaired lymphatic drainage
associated with solid tumors [5]. Compared with non-targeting
liposomes, active-targeting liposomes that involve the use of
attached specific ligands more effectively enhance the anticancer
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activity of the encapsulated drug, as ligand-mediated endocytosis
helps facilitate the uptake of the actively delivered drug [6]. Human
epidermal growth factor receptor-2 (HER2) is a 185 kDa type I
receptor tyrosine kinase glycoprotein that is often overexpressed in
breast, ovarian, colon, and lung cancer tissues [7]. HER2
overexpression in human breast cancer cells increases their
metastatic potential and is associated with a poor prognosis.
Therefore, HER2 has been considered as a target for cancer
therapy [8]. Liposomal drug delivery targeting HER2 has been well
studied, and immunoliposomes displaying anti-HER2 antibodies
such as trastuzumab exhibit greater anticancer activity than non-
targeting liposomes by specifically targeting HER2-overexpressing
cancer cells [9–12].
Several attempts are currently underway to encapsulate PTX
into liposomes. PTX is too hydrophobic to be encapsulated into
the inner water core of liposomes and in previous studies PTX has
been inserted into the hydrophobic space of a lipid bilayer to
generate active liposomes constructs [13–17]. However, to prepare
stable liposomes with significant amounts of drug, PTX should be
encapsulated into the inner water core of liposomes instead of
inserted into the lipid bilayer. In the case of Doxil, doxorubicin is
encapsulated into the inner water core of liposomes using a unique
procedure of remote loading with an ammonium sulfate gradient
[18]. A similar remote loading approach could be applied to
achieve efficient encapsulation of PTX into the inner water core of
liposomes.
In this paper, we demonstrate that glycosylated PTX (7-
glucosyloxyacetylpaclitaxel; gPTX), which is a more hydrophilic
PTX derivative with a glucose moiety coupled at 7-OH of PTX
[19], is more efficiently encapsulated into the inner water core of
liposomes than PTX. We also report encapsulation of sufficient
amounts of gPTX using a novel remote loading method with a
solubility gradient allowing high efficiency. Furthermore, targeted
drug delivery was evaluated by constructing immunoliposomes
with trastuzumab.
Materials and Methods
Materials
Dipalmitoylphosphatidylcholine (DPPC), 1,2-distearoyl-sn-glycer-
ol-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]
(mPEG–DSPE), and 1,2-distearoyl-sn-glycerol-3-phosphoethanola-
mine-N-[maleimide (polyethylene glycol)-2000] (Mal–PEG–DSPE)
were obtained from NOF Co. (Tokyo, Japan). Cholesterol (Chol)
was purchased from Kanto Chemical Co., Inc. (Tokyo, Japan).
Thiazolyl blue tetrazolium bromide (MTT), RPMI 1640 medium
and DMEM were obtained from Sigma-Aldrich (St Louis, MO,
USA). Trastuzumab was a generous gift from Chugai Pharmaceu-
tical. CO., LTD. (Tokyo, Japan). gPTX was synthesized as
previously described [19].
Cell culture
The human colon cancer cell line HT-29 (ATCC, Manassas,
VA, USA) and the human breast cancer cell line SK-BR-3
(ATCC) were cultured in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS) and 100 mg/mL kanamycin. The
human breast cancer cell line MDA-MB-231 (ATCC) was
cultured in DMEM supplemented with 10% FBS and 100 mg/
mL kanamycin. Cells were maintained at 37uC in an atmosphere
of 5% CO2.
Evaluation of gPTX solubility
The difference in hydrophilicity between gPTX and PTX was
evaluated using a C18 reverse-phase HPLC column (GL Sciences
Inc., Tokyo, Japan) under isocratic elution with 55% (v/v)
methanol at a flow rate of 1 mL/min. PTX or gPTX at 5 mg/
mL was injected at a volume of 10 mL and detected at 227 nm.
The maximum solubility of PTX and gPTX in 40% (v/v)
ethylene glycol (EG) was determined as follows. First, 2 mg of
PTX or gPTX were dissolved in 1 mL of 40% EG followed by
three rounds of sonication for 10 min. The solution was then
centrifuged at 12,0006g for 20 min and the supernatant was
analyzed for the concentration by reverse-phase HPLC under
isocratic elution with 60% (v/v) methanol at a flow rate of 1 mL/
min.
The maximum solubility of PTX or gPTX in Cremophor EL/
ethanol/PBS (12:12:76 volume ratio) (CEP) was determined by
gelation after adding different amounts of PTX or gPTX in 1 mL
of CEP.
Tubulin polymerization assay
The stability of tubulin polymerization was evaluated using the
Tubulin Polymerization Assay Kit (Cytoskeleton Inc., Denver,
USA) according to the manufacturer’s instructions. In brief, 2 mg/
mL porcine tubulin in tubulin polymerization buffer containing
80 mM PIPES pH 6.9, 2.0 mM MgCl2, 0.5 mM EDTA, 1.0 mM
GTP, and 10 mM fluorescent reporter was prepared. Then tubulin
solution was transferred to a prewarmed 96-well plate that
contained 3 mM PTX or gPTX. The polymerization of tubulin
was monitored as fluorescence at 37uC for 60 min, and the
reading speed was programmed at 1 cycle/min with excitation
and emission wavelengths of 360 and 420 nm, respectively, using
the MTP-800 microplate reader (Corona Electric, Ibaraki, Japan).
The stability of polymerization was judged by the differences of
fluorescence intensities in the presence or absence of PTX or
gPTX. The experiment was independently performed in triplicate
and the mean and standard deviation (S.D.) of the fluorescent
intensities were calculated.
Preparation of liposomes containing PTX/gPTX
Liposomes composed of DPPC and Chol with 5 mol% mPEG–
DSPE were prepared by the thin-film hydration method. In brief,
DPPC and Chol with 5 mol% mPEG–DSPE were dissolved in an
organic solvent of chloroform/methanol (9:1 v/v) in an egg flask.
The flask was connected to a rotary evaporator, which was
maintained at 45uC under aspirator vacuum. The resulting lipid
film was left overnight under vacuum to remove remaining
organic solvent. The completely dehydrated lipid film was
suspended in CEP by vortexing at 60uC, resulting in the formation
of multilamellar vesicles (MLVs). MLVs were sonicated twice by
the Sonicator 3000 (Misonix, NY, USA) equipped with 3.2 mm
micro tip for 5 min at 60uC to form small lamellar vesicles (SLVs).
The outer solvent of the liposomes was replaced CEP with PBS by
ultrafiltration with a 100K-membrane filter (Merck Millipore Ltd.,
Billerica, USA) at 12,0006g for 20 min for five times. Then, PTX
(0.1 mg/mL) or gPTX (1 mg/mL) in 40% EG was added into the
solution of liposome encapsulating CEP (CEP-L) at 60uC. Thus,
PTX- or gPTX-containing liposomes (PTX- or gPTX-L) were
prepared under the solubility gradient, which is a remote loading
method. The initial ratio of the PTX or gPTX to initial lipids/
Chol at the remote loading was 0.005 or 0.05 (w/w). PTX- or
gPTX-L was then concentrated to the volume before added drug
by ultrafiltration. This encapsulation process was conducted three
times. Finally, residual PTX or gPTX was removed by washing
the liposomes with PBS followed by ultrafiltration at 12,0006g for
20 min for five times.
For the direct encapsulation, the lipid film was suspended in
CEP-dissolved PTX or gPTX at a concentration of 0.3 or 3 mg/
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mL with the initial ratio of PTX or gPTX to initial lipids/Chol
0.016 or 0.16 (w/w) as described above for the preparation of
CEP-L. The drug-encapsulating MLVs were further sonicated to
prepare SLVs, and the residual drug was removed by washing the
liposomes with PBS as described above.
Evaluation of the influence of lipid compositions and
incubation time for encapsulation
The influence of different molar ratios of DPPC to Chol of 3:1,
3:2, and 3:3 was evaluated in the solubility gradient method. To
encapsulate the drug, 1 mg/mL gPTX in 40% EG and CEP-L
were incubated for 30 min at 60uC. The encapsulation efficiency
(EE) was assessed by HPLC. The stability of gPTX-L in different
lipid compositions was evaluated in RPMI 1640 medium
supplemented with 10% FBS at 37uC. Drug retention according
to the time course was assessed by HPLC. The influence of the
incubation time was evaluated when the molar ratio of DPPC to
Chol was 3:1.
Preparation of immunoliposomes containing gPTX
To prepare HER2-targeting immunoliposomes containing
gPTX (gPTX-IL), gPTX-L displaying trastuzumab on the surface
of the liposome was prepared. CEP-L composed of DPPC and
Chol with 4 mol% mPEG–DSPE were incubated with 1 mol%
Mal–PEG–DSPE at 50uC for 10 min to introduce maleimide
functional groups to conjugate antibodies [20]. Then, gPTX was
encapsulated using the solubility gradient method described above.
To immobilize antibody on the surface of the liposomes, SH
groups were introduced into trastuzumab by treatment with 2-
iminothiolane at a molar ratio of 1:50 in 25 mM HEPES, pH 8.0
containing 140 mM NaCl. The mixture was subsequently
incubated for 1 h at room temperature in the dark [20,21]. After
purification by gel chromatography with a G25 PD-10 column
(GE Healthcare, Tokyo, Japan), trastuzumab was incubated with
liposomes containing Mal–PEG–DSPE overnight at 4uC. Free
trastuzumab was removed by ultrafiltration with a 300K-
membrane filter (Sartorius Stedim Biotech GmbH, Gottingen,
Germany) at 60006g for 20 min.
Evaluation of Encapsulation efficiency (EE) and loading
efficiency (LE)
EE was calculated as the ratio of the amount of PTX/gPTX
encapsulated into liposomes to the initial amount of the drug. LE
was calculated as the molar ratio of the drug encapsulated into
liposomes to the total of lipids and Chol. The amount of
encapsulated drug was evaluated by C18 reverse-phase HPLC
under an isocratic condition of 60% (v/v) methanol at a flow rate
of 1 mL/min. Ten mL of each sample were injected and the drug
was detected at 227 nm.
Particle size and zeta potential
The particle size and zeta potential of liposomes were
determined by dynamic light scattering and electrophoretic light
scattering with an ELS-8000 microscope (Otsuka Electronics,
Osaka, Japan).
Transmission electron microscope (TEM) image of PTX-L
and gPTX-L
The liposome samples were negatively stained with tungsten
phosphate, and observed with a TEM (H-7600, Hitachi, Tokyo,
Japan) at an accelerating voltage of 100 kV. The TEM study was
conducted by Hanaichi Ultra-Structure Research Institute (Aichi,
Japan).
Evaluation of concentration-dependent cytotoxic effects
In vitro cytotoxicity was evaluated by the MTT assay after 72 h
of drug exposure. HT-29, SK-BR-3 and MDA-MB-231 cells were
seeded in a 96-well plate at 5.06103 cells/well. After incubation at
37uC in 5% CO2 for 24 h, different concentrations of PTX or
gPTX were added to each well. After incubation for 72 h, 5 mg/
mL MTT solution was added at a final concentration of 0.6 mg/
mL in each well and the plate was incubated for 4 h. Formed
formazan crystals were dissolved in 10% (w/v) SDS with 0.02 N
HCl and incubated overnight. Finally, the absorbance of each well
was measured at 570 nm using an MTP-800 microplate reader.
The experiment was independently performed in triplicate. The
concentrations at which cell growth was inhibited by 50% (IC50)
and 100% (IC100) were estimated from the survival curve.
Evaluation of time-dependent cytotoxic effects
Time-dependent cellular cytotoxicity was evaluated by the
MTT assay with drugs at IC100. HT-29, SK-BR-3 and MDA-MB-
231 cells were seeded in a 96-well plate at 5.06103 cells/well.
After incubation at 37uC in 5% CO2 for 24 h, drugs at their IC100
were added to each well and incubated for 1, 2, 6, 12, 24, 48, and
72 h. After each round of drug exposure, the medium was
replaced with fresh medium without drugs and the incubation was
continued for an additional 72 h after the drugs were added. Cell
viability was determined by MTT assay. The time required for
50% growth inhibition (IT50) was estimated from the survival
curve.
Animal experiments
Animal experimental protocols were reviewed and approved by
the ethics committee for animal experiments of Okayama
University under the IDs OKU-2012203 and OKU-2014156.
Evaluation of acute toxicities of drugs in vivo
The acute toxicities of the drugs were evaluated with female
BALB/c mice (Charles River, Kanagawa, Japan). Mice were bred
at 23uC and fed with sterilized food and water. Naked gPTX.
gPTX-L and gPTX-IL at the dose of 150 mg/kg gPTX were
intravenously injected into 6-week-old mice via tail vein twice in
3 h. As a control, the equivalent amount of CEP contained naked
gPTX and the equivalent amount of PBS contained in gPTX-IL
was injected into mice. The body weights were monitored for 2
weeks. Mice with more than 20% body weight loss were sacrificed
for humane reasons.
Evaluation of the antitumor effects of drugs in vivo
To prepare tumor-bearing mice, 36106 HT-29 cells were
subcutaneously injected into 5-week-old female BALB/c-nu/nu
mice (Charles River, Kanagawa, Japan). Mice were bred at 23uC
and fed with sterilized food and water. When tumor volumes
reached 50–200 mm3, mice were randomly divided into several
groups, with three or four mice in each group. Naked gPTX,
gPTX-L, gPTX-IL, mixture of gPTX-L and trastuzumab,
trastuzumab only, CEP only, immunoliposomes encapsulating
CEP only (CEP-IL), or PBS was intravenously injected via the tail
vein twice in 3 h. The total injected dose of naked gPTX was
100 mg/kg. gPTX-L was injected at the gPTX-equivalent dose of
150 mg/kg. gPTX-IL was injected at the gPTX-equivalent dose of
10 to 150 mg/kg. As the control, the equivalent amount of CEP
contained in the naked gPTX at the dose of 100 mg/kg was
injected into mice. CEP-IL was also injected as the control at a
concentration at which the amount of lipid equivalent to that
contained in gPTX-IL at the gPTX-equivalent dose of 150 mg/
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kg. Trastuzumab (150 mg/kg) was injected at the same concen-
tration of trastuzumab conjugated to gPTX-IL at the gPTX-
equivalent dose of 150 mg/kg. Tumor volumes and body weights
were measured at 3-day intervals. The tumor volume was
calculated using the formula 0.56 width2 6 length, in which
width is the smallest diameter and length is the longest diameter.
The mice were sacrificed at day 30 and the tumors were weighed.
The antitumor effect by repeated administration was evaluated
in HT-29 cell-bearing BALB/c-nu/nu mice. Mice were randomly
divided into several groups, with for mice in each group. The mice
treated with gPTX-L, gPTX-IL, mixture of gPTX-L and
trastuzumab, CEP-L, CEP-IL, trastuzumab, or PBS were intra-
venously injected via the tail vein 3 times at day 0, 10 and 20 with
the gPTX-equivalent dose of 150 mg/kg at each time. Tumor
volumes and body weights were measured at 3 or 4-day intervals.
Mice with more than 20% body weight loss or tumors larger than
2,500 mm3 were sacrificed for humane reasons.
Statistical analysis
The results are presented as the mean 6 S.D. where necessary.
Statistical analyses were performed using Student’s t-test. P,0.05
was considered statistically significant.
Results
Characterization of gPTX
The hydrophilicity of gPTX was evaluated by C18 reverse-phase
HPLC (Fig. 1A). The retention time of gPTX was 33.3 min
whereas that of PTX was 35.9 min, indicating that gPTX was
more hydrophilic than PTX. The hydrophilicity was further
assessed by evaluating solubility in 40% EG and CEP. The
maximal solubility of gPTX was 1.10 mg/mL in 40% EG and
20.0 mg/mL in CEP, whereas that of PTX was 0.12 mg/mL in
40% EG and 2.0 mg/mL in CEP. These results indicate that
gPTX had a 10-fold higher solubility than PTX in these solvents.
These data are summarized in Table 1.
Since the mechanism of PTX anticancer activity is based on the
inhibition of tubulin depolymerization, gPTX tubulin stabilization
activity was compared with that of PTX (Fig. 1B). gPTX induced
slower polymerization than PTX and the maximal tubulin
polymerization mediated by gPTX was 89.964.1% of that
induced by PTX. This result suggests that gPTX exhibits almost
equivalent inhibition of tubulin depolymerization, although the
affinity of gPTX for b-tubulin may be lower than that of PTX
because of the glucose moiety.
Preparation and characterization of gPTX-L and gPTX-IL
To encapsulate large amounts of gPTX into the inner water
core of liposomes, we first attempted a direct encapsulation
approach. In this method, the thin-film lipid layer was rehydrated
with the solvent-dissolved gPTX at the maximal concentration.
Since observed EE and LE were less than 1% and 0.1%,
respectively, gPTX at the maximal concentration in 40% EG
(1 mg/mL) was found inadequate for effective encapsulation
(Table S1). In contrast, we found CEP more useful as the solvent
for gPTX encapsulation than 40% EG. CEP-dissolved gPTX at
the maximal concentration (20 mg/mL) showed 17.6% of EE and
13.7% of LE. However, the EE obtained by direct encapsulation
with CEP is still less than 20%, and an EE of more than 60% is
required for clinical application.
To achieve more efficient encapsulation, we evaluated a remote
loading strategy with a solubility gradient between 40% EG and
CEP (Fig. 2). To optimize the lipid composition for gPTX-L,
different DPPC/Chol ratios were assessed by remote loading
under the solubility gradient. DPPC:Chol at a molar ratio of 3:1
appeared suitable in regards to EE and retention rate in 10% FBS
at 37uC (Fig. 3A, B). We next evaluated various incubation times
at 60uC for the encapsulation of gPTX under these parameters,
and found that 15 min of incubation achieved the highest EE
(Fig. 3C). Thus, liposomes composed of DPPC and Chol at a
molar ratio 3:1 with 5 mol% mPEG–DSPE and an incubation
period of 15 min for drug encapsulation were used for the
subsequent experiments.
Encapsulation of gPTX under these conditions by remote
loading showed 70.8% of EE and 8.0% of LE, whereas direct
encapsulation in CEP showed 44.6% of EE and 5.0% of LE
(Fig. 4A, B). The observed diameter of gPTX-L was almost
equivalent in both encapsulation methods, at approximately 140
to 150 nm (Fig. 4C). The EE of PTX by the solubility gradient
method was almost equivalent to that of gPTX. They exhibited
liposomal formulations in TEM images (Fig. 4E). However, the
LE of gPTX-L was 8-fold higher than that of PTX-L because of
the higher solubility of gPTX compared to that of PTX.
Furthermore, PTX-L was unstable in PBS at 4uC, exhibiting a
retention rate of drug as low as 44.4% in 4 days, whereas gPTX-L
was stable during the same period after the preparation of
liposomes (Fig. 4D). In addition, gPTX-L was stable enough to
Figure 1. Characterizations of gPTX. A, The hydrophobicity of PTX
and gPTX was evaluated by reverse-phase HPLC using a C18 column at a
flow rate of 1 mL/min with 55% (v/v) methanol under an isocratic
condition. B, The ability of 3 mM PTX (open circle) and gPTX (open
triangle) to stabilize porcine tubulin polymerization was evaluated
using a Tubulin Polymerization Assay Kit (Cytoskeleton). The fluorescent
reporter was detected with excitation at 360 nm and emission at
420 nm. Each dot represents the mean 6 S.D. (n = 3).
doi:10.1371/journal.pone.0107976.g001
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exhibit a retention rate of 97.6% without significant change in
particle size (65.3 nm) after 4 weeks of incubation in PBS at 4uC.
To confer gPTX-L with active targeting potential, trastuzumab
was conjugated onto the surface of liposomes to prepare gPTX-IL.
The mean particle size of gPTX-IL was approximately 150 nm,
which is the optimal size for solid tumor targeting based on EPR
effects. The zeta potentials of gPTX-L and gPTX-IL were 2
3.462.9 mV and 23.761.3 mV, respectively. The liposomal
formulation of gPTX-IL was also observed in TEM image (Fig.
S1).
Cytotoxicity of gPTX, gPTX-L and gPTX-IL in vitro
We next evaluated the cytotoxicity of different formulations of
gPTX in two HER2-overexpressing cancer cell lines, HT-29 and
SK-BR-3, and in the HER2 low-expressing cancer cell line MDA-
MB-231 by the MTT assay [7,22]. IC50 and IC100 were evaluated
after 72 h of exposure to the drugs (Fig. 5A and Table S2). gPTX-
L and gPTX-IL exhibited enhanced IC50 compared to gPTX,
while gPTX-IL exhibited a similar IC50 as gPTX-L independent
of HER2 expression (Fig. 5A). When IT50 was evaluated at IC100,
the shortest IT50 of gPTX-IL was observed following the
treatment of HER2-overexpressing HT-29 and SK-BR-3 cells,
whereas IT50 was not different between gPTX-L and gPTX-IL in
the treatment of HER2 low-expressing MDA-MB-231 cells
(Fig. 5B and Table S2). These results suggested that gPTX-IL
targeted HER2-expressing cells more efficiently than gPTX-L
together with the feasible cytotoxicity mediated by the liposomal
formulation.
Acute toxicity of gPTX, gPTX-L and gPTX-IL in vivo
Acute toxicity and the lethal dose of gPTXwere next evaluated in
BALB/c mice (Fig. 6 and S2). The lethal dose of naked gPTX was
150 mg/kg, with a survival rate of 25 to 50%. The survival rate of
mice treated with the amount of CEP required to dissolve the lethal
dose of gPTX was 50 to 75%. However, 150 mg/kg of gPTX in the
liposomal formulation did not exhibit any toxicity, even when
gPTX dissolved in CEP was encapsulated into liposomes. Naked
gPTX induced a significant loss of body weight for more than a
week after injection, whereas gPTX-L and gPTX-IL did not
significantly affect body weight.
Table 1. Solubility of PTX and gPTX in different solvents.
Solvent Max. solubility (mg/mL)
PTX gPTX
*H2O 0.4610
23 2361023
40% EG 0.12 1.10
**CEP 2.0 20.0
* Solubility of H2O was referred as described previously [19].
** CEP consists of Cremophor EL and ethanol in PBS (12:12:76 volume %).
doi:10.1371/journal.pone.0107976.t001
Figure 2. Schematic illustration of remote loading with a
solubility gradient. CEP-encapsulated liposomes (CEP-L) and gPTX
dissolved in 40% EG were mixed and incubated. gPTX was encapsulated
into liposomes under a solubility gradient.
doi:10.1371/journal.pone.0107976.g002
Figure 3. Influence of the lipid composition and incubation
time for drug encapsulation by the solubility gradient method.
A, The encapsulation efficiency (EE) of gPTX-L with various lipid
compositions was evaluated after 30 min of incubation for gPTX
encapsulation. B, The drug retention of gPTX-L with different lipid
compositions was evaluated in medium supplied with 10% FBS at 37uC.
C, The efficiency of drug encapsulation under different durations of
incubation was evaluated with a DPPC to Chol ratio of 3:1.
doi:10.1371/journal.pone.0107976.g003
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Figure 4. Comparison of the encapsulation efficiency (EE), loading efficiency (LE), and particle size. A, EE. B, LE. C, particle size. #Control
indicated that gPTX-L was prepared with liposomes encapsulating 40% EG in 1 mg/mL gPTX. Comparison of stability at 4uC in PBS with PTX-L and
gPTX-L prepared by the solubility gradient method. D, The retention rates of PTX-L (open circle) and gPTX-L (open triangle) were evaluated by HPLC.
E, TEM images of PTX-L and gPTX-L. Each formulation was observed after 4 days of incubation. Each data point is presented as the mean 6 S.D.
(n = 3). *, P,0.05.
doi:10.1371/journal.pone.0107976.g004
Figure 5. Cytotoxicity of different gPTX formulations by the MTT assay. A, The IC50 values after drug exposure for 72 h are shown. B, The
IT50 values at IC100 are shown. The data are presented as the mean 6 S.D. for three independent experiments. *, P,0.05. **, P,0.01. ***, P,0.005.
****, P,0.001. NSD, no significant difference.
doi:10.1371/journal.pone.0107976.g005
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Suppression of tumor growth by gPTX-IL in vivo
The in vivo antitumor effects of different gPTX formulations
were evaluated in tumor-bearing mice that had been transplanted
with HT-29 cells. Although a single administration of gPTX-L
with/without trastuzumab at a gPTX-equivalent dose of 150 mg/
kg did not suppress tumor growth, gPTX-IL decreased tumor
weight in a dose-dependent manner and the gPTX-equivalent
doses of both 100 and 150 mg/kg of gPTX-IL significantly
suppressed tumor growth without affecting body weight (Fig. 7).
We further evaluated the antitumor effect of repeated adminis-
tration of the total dose of 450 mg/kg (Fig. 8). gPTX-IL showed
the most effective suppression of tumor growth without significant
loss of body weight. The mice treated with gPTX-IL exhibited the
longest 50% survival period more than 90 days after the first
administration.
Discussion
In this study, the ability of gPTX to stabilize tubulin
polymerization was 90% of that of PTX (Fig. 1). Although this
level of activity should be sufficient to inhibit cell growth and
proliferation, the IC50 of gPTX was 3–10-fold higher than that of
PTX (Fig. 5A). This apparent discrepancy between the tubulin
stabilization activity and the observed inhibition of cell growth
could be due to the hydrophilicity of gPTX, since the efficiency of
penetration into the lipid bilayer of the cell membrane depends on
hydrophobicity. As a result, gPTX exhibited weaker cytotoxicity
than PTX. In this context, gPTX may be safer than PTX with
respect to the potential for side effects when administered in vivo.
A suitable formulation of gPTX to efficiently penetrate the cell
membrane should enhance the availability as an anticancer drug
more effectively than PTX. It appears that the immunoliposome
formulation should be applicable to confer gPTX with penetra-
bility. Since we found that gPTX was soluble in 40% EG and
CEP, we first attempted direct encapsulation of gPTX into
liposomes in these solvents, but the EE was not practical to
prepare enough gPTX-L for clinical application (Table S1).
The remote loading method is a typical method to facilitate
efficient encapsulation of drugs into the inner water core of
liposomes. PEGylated liposome-encapsulated doxorubicin, known
as Doxil, is prepared by the ammonium sulfate gradient remote
loading method [18]. The application of a pH gradient method
was developed for the encapsulation of a derivative of docetaxel
modified with a weak base group [23]. However, this method is
not considered suitable for the encapsulation of uncharged drugs
such as taxanes. Hence, we developed an approach to use the
different solubilities of gPTX in solvents in the remote loading
procedure. We developed a novel remote loading method using a
solubility gradient between 40% EG and CEP to achieve efficient
Figure 6. Acute toxicity of the drugs in vivo. gPTX (open circle),
gPTX-L (open triangle) or gPTX-IL (open diamond) at a concentration of
150 mg/kg, CEP (open square), or PBS (cross) was intravenously injected
into 6-week old female BALB/c mice. A, Changes in body weight. B,
Survival rate. Data are presented as the mean 6 S.D. (n = 4). gPTX is not
shown S.D. after day 3. NSD, no significant difference.
doi:10.1371/journal.pone.0107976.g006
Figure 7. Anticancer efficacy of different gPTX formulations
with single administration in HT-29 cells tumor-bearing mice.
When the tumor volume reached 50–200 mm3, gPTX-IL at the dose of
150 (open circle with solid line), 100 (open circle with broken line), 50
(brown circle with solid line), or 10 mg/kg (brown circle with broken
line), gPTX-L at the dose of 150 mg/kg (open triangle), gPTX-L at the
dose of 150 mg/kg with 150 mg/kg trastuzumab (gPTX-L + Tras, open
square), naked gPTX at the dose of 100 mg/kg (open diamond),
trastuzumab (Tras, closed square), CEP-IL (closed circle), or PBS (cross)
was intravenously injected. A, Tumor weights at day 30. B, Changes in
body weight. Data are presented as the mean 6 S.D. *, P,0.05
compared with PBS.
doi:10.1371/journal.pone.0107976.g007
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encapsulation of gPTX and PTX into liposomes (Fig. 4A–C).
When gPTX dissolved in 40% EG was added to 40% EG-
encapsulated liposomes, EE was ,10%. This result suggested that
the solubility gradient acted as a driving force for active
encapsulation. This is the first report of an efficient method for
encapsulating uncharged molecules such as PTX and its derivative
into liposomes by a remote loading method.
PTX-L was labile even when maintained at 4uC, and TEM
image revealed that it existed as a nonliposomal formulation after
4 days of incubation at 4uC. This is likely because sufficient
amounts of PTX accumulated in the hydrophobic space in the
lipid bilayer, resulting in the breakdown of the liposomes and
subsequent release of free PTX. This might be the reason why the
amounts of PTX encapsulated into liposomes is limited, although
liposome encapsulated-PTX in which PTX is inserted into the
lipid bilayer has been demonstrated [17]. In contrast, gPTX-L
prepared by remote loading displayed almost 100% retention rate
during 4 weeks of incubation at 4uC. These results suggested that
most gPTX is efficiently encapsulated into the inner water core of
liposomes by the solubility gradient method. The hydrophilic
character of gPTX compared to PTX could explain the good
retention of gPTX in the inner water core of liposomes.
Although Cremophor EL and ethanol are toxic, the commercial
formulation of PTX, Taxol, contains both as the solvent. Thus, the
development of liposomal PTX has been an important issue for
the use of this drug as an effective anticancer agent to avoid the
toxicity of the solvent and improve the efficacy of Taxol. In the
solubility gradient method, the solvent is directly encapsulated into
the liposomes. CEP-L should have fewer side effects than free CEP
because the compounds should be simultaneously delivered to
tumor tissues. This hypothesis was confirmed in the in vivo
experiment (Figs. 8 and S4). CEP-L did not cause serious side
effects such as loss of body weight in vivo, whereas free CEP was
toxic in the assessment for acute toxicity (Fig. S2).
To enhance the therapeutic effect of gPTX-L, we designed
immunoliposomes to target HER2 by displaying trastuzumab on
the surface of the liposomes. An in vitro cytotoxic assay after 72 h
of drug exposure revealed that gPTX-L exhibited enhanced
cytotoxicity compared with gPTX. This result suggests that large
amounts of gPTX simultaneously internalize into the cells with the
liposomal formulation. The IC50 of gPTX-IL was almost similar to
that of gPTX-L, even in HER2-overexpressing cancer cells.
However, gPTX-IL effectively suppressed the growth of HER2-
overexpressing cancer cells at the shortest IT50 among the
formulations. Thus, these results suggest that gPTX-IL efficiently
targets and internalizes into HER2-overexpressing cancer cells via
HER2-mediated endocytosis [14,24].
Liposomal formulation of PTX decreased the side effects of
naked PTX because PTX is not bioavailable until PTX is released
from liposomes [16,25]. We also demonstrated that liposomal
formulation of gPTX decreased the side effects of naked gPTX
(Fig. S2). The naked gPTX at the dose of 150 mg/kg was lethal to
mice and at both doses of 100 and 150 mg/kg gPTX showed
significant loss of body weights. However, the mice treated with
gPTX-L at the same doses of naked gPTX dramatically alleviated
the acute toxicity. gPTX-IL at the dose of 150 mg/kg also
Figure 8. Anticancer efficacy of different gPTX formulations with repeated administration in HT-29 cells tumor-bearing mice. gPTX-
IL (open circle with line), gPTX-L (open triangle), gPTX-L with trastuzumab (open square), trastuzumab (closed square), CEP-IL (closed circle), CEP-L
(closed triangle), or PBS (cross) was intravenously injected at day 0, 10, and 20. The dose of each administration was 150 mg/kg gPTX. A and B,
Changes in tumor volume. C, Changes in body weight. D, Survival curves. Data are presented as the mean 6 S.D. The changes of tumor volume and
body weight in the mice administered with gPTX-L do not show S.D. after day 10. The P value shown compared with gPTX-IL and gPTX-L with
trastuzumab treated group at day 43 (n = 4). *, P,0.05.
doi:10.1371/journal.pone.0107976.g008
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decreased the side effects of gPTX such as significant loss of body
weight and lethality just as gPTX-L did (Fig. 6). PTX encapsu-
lated into liposomes have showed large amounts of PTX
accumulate into the liver of the mice [13,26,27]. Reticuloendo-
thelial system such as the liver is a major mechanism for clearance
of the liposomes [28]. Drugs encapsulated into liposomes should
be excreted via liver tissue together with bile acids. Once PTX is
excreted into intestine it will not be reabsorbed due to P-
glycoprotein as well as the enzymatic degradation [29]. Since PTX
itself is considered to be metabolized predominantly in the liver
with cytochrome P450 [30]. Cytochrome P450 enzymatically
detoxifies PTX while highly excess dose of PTX should still be
lethally toxic. Taking these into consideration, gPTX in liposomes
should be excreted into intestine where P-glycoproteins prevent
reabsorption. On the other hand, naked gPTX is metabolized by
cytochrome P450 in the liver while the excess amount of gPTX
would affect the whole of the body. Therefore, it is conceivable
that liposomal formulation of gPTX alleviates the side effects of
gPTX.
Finally, we evaluated the antitumor effects of gPTX-L and
gPTX-IL in vivo. While treatment of mice with naked gPTX at
the dose of 100 mg/kg significantly decreased body weight,
treatment with gPTX-L and gPTX-IL did not significantly affect
body weight even when the gPTX-equivalent dose was 150 mg/
kg, which was lethal when gPTX dissolved in CEP was directly
injected into the mice. Although gPTX-L at the gPTX-equivalent
dose of 150 mg/kg did not suppress tumor growth, gPTX-IL at
the equivalent dose decreased tumor volume and effectively
suppressed tumor growth in HT-29 tumor-bearing BALB/c-nu/
nu and ICR-nu/nu mice in single administration experiments
(Figs. 7 and S4). We further evaluated antitumor efficiency with
repeated administration at the total dose of 450 mg/kg gPTX.
Both gPTX-L and -IL effectively inhibited tumor growth.
Furthermore, gPTX-IL exhibited the most effective antitumor
activity without side effects, such as a loss of body weight (Fig. 8).
We confirmed that liposomes accumulated at the tumor site in
HT-29 tumor-bearing mice via EPR effects, and trastuzumab-
displaying immunoliposomes exhibited a longer retention time at
the tumor site than non-targeting liposomes (Fig. S3). Immuno-
liposomes efficiently internalize into cancer cells at the tumor site
while non-targeting liposomes localize in the stroma of tumor
tissue [31]. In this regard, gPTX-IL effectively internalized into
the tumor cells and strongly inhibited tumor growth. On the other
hand, gPTX-L did not exhibit same antitumor activity as gPTX-
IL because non-targeting liposomes did not have a sufficient
retention time to affect tumor growth.
Nanoparticle-based PTX formulations, Abraxane (albumin-
bound PTX) and Lipusu (liposome-encapsulated PTX), have been
commercially and clinically available. The 50% lethal dose (LD50)
of each drug in mice was reported at the PTX-equivalent dose of
47 and 70 mg/kg, respectively [32,33]. The LD50 of our gPTX-L
was more than 150 mg/kg of gPTX. Taking into account the
molecular weights and tubulin polymerization assay results, the
dose of 150 mg/kg of gPTX is equivalent to the dose of 100 mg/
kg of PTX. Furthermore, gPTX-IL was also injected at the gPTX-
equivalent dose of 150 mg/kg in single administration experi-
ments. Yang et al. previously reported trastuzumab-displaying and
PTX encapsulating liposomes [12,14]. The antitumor activity of
their PTX-immunoliposomes was evaluated at the PTX-equiva-
lent total dose of 22.5 mg/kg (three administrations of PTX
equivalent of 7.5 mg/kg with a 4-day interval) [12]. The PTX-
equivalent dose of our gPTX-IL in antitumor effect of the repeated
administration was estimated to be 13-fold higher than that of
their PTX-immunoliposomes. Our gPTX-IL thus could be used
for drug formulations to enable administration with high effective
anticancer activity in patients with HER2 overexpressing cancer
cells.
Together our results show that gPTX was efficiently encapsu-
lated into liposomes via the novel encapsulation strategy including
a solubility gradient. Immunoliposomes encapsulated gPTX
successfully exhibited efficient anticancer activity against HER2-
overexpressing cancer cells in vitro and in vivo. Thus, we propose
gPTX-IL should be an excellent candidate as a targeted drug
delivery system.
Conclusions
gPTX generated by coupling a glucose moiety at the 7-OH
residue of PTX allowed encapsulation of the drug into liposomes
with high efficiency without a significant decrease in its ability to
stabilize tubulin polymerization. The cytotoxic activity of gPTX
was significantly less than that of PTX, suggesting that the
hydrophilic character of gPTX could prevent the molecule from
permeating through the lipid bilayer of cells. Encapsulation of
gPTX into liposomes with high efficiency was successfully
achieved by the novel remote loading strategy under a solubility
gradient between CEP and 40% EG. This strategy should enable
the preparation of sufficient quantities of both gPTX-L and
gPTX-IL for practical therapy. Notably, the cytotoxicity of gPTX-
IL was dependent on the exposure time, suggesting that the
potential of immunoliposomes should be high in targeting cell
surface antigens. As expected, gPTX-IL strongly inhibited tumor
growth of HER2-overexpressing cancer cells with less side effects
in vivo. Taken together, the immunoliposomes containing
effective amounts of gPTX should be a promising formulation of
anticancer drugs for targeted drug delivery systems with gPTX.
Supporting Information
Figure S1 TEM image of gPTX-IL. The formulation was
observed with TEM.
(TIF)
Figure S2 Acute toxicity of gPTX and gPTX-L in vivo.
gPTX (open circle) or gPTX-L (closed circle) at a concentration of
150 mg/kg, gPTX (open triangle) or gPTX-L (closed triangle) at a
concentration of 100 mg/kg, CEP (open square), or PBS (cross)
was intravenously injected into 6-week old female BALB/c mice.
A, Changes in body weight. B, Survival rate. Data are presented as
the mean6 S.D. (n = 4). gPTX at the concentration of 150 mg/kg
and CEP are not shown S.D. after day 1.
(TIF)
Figure S3 Distribution of HSA-Cy5.5 in tumor-bearing
ICR-nu/nu mice transplanted with HT29 cells. When the
tumor volume reached 100–200 mm3, HSA-Cy5.5-IL, HSA-
Cy5.5-L, free HSA-Cy5.5, and HSA as a control were
intravenously injected into mice. Cy5.5 fluorescence was detected
2, 4, 6, 12, 24, and 48 h after injection. Each arrow indicates the
location of tumor tissue.
(TIF)
Figure S4 Anticancer efficacy of different gPTX formu-
lations in tumor-bearing ICR-nu/nu mice transplanted
with HT-29 cells. When the tumor volume reached 50–
200 mm3, gPTX-IL (open circle), gPTX-L (open triangle), CEP-
IL (closed circle), CEP-L (closed triangle), trastuzumab (closed
square), or PBS as a control (cross) was intravenously injected at a
dose of 150 mg/kg gPTX on day 0. A and B, Changes in tumor
volume. C, Changes in body weight. Data are presented as the
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mean 6 S.D. (n = 4). *, P,0.05 at day 30 for gPTX-IL compared
with the other treatments.
(TIF)
Table S1 Encapsulation efficiency (EE) and loading
efficiency (LE) of PTX-L or gPTX-L in a direct encapsu-
lation method with 40% EG and CEP at the maximal
concentration.
(DOCX)
Table S2 Cytotoxicity of different PTX formulations in
HER2-overexpressing cancer cells (HT-29 and SK-BR-3)
and HER2 low-expressing cancer cells (MDA-MB-231).
(DOCX)
Methods S1 (DOCX)
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